8-K

CVS HEALTH CORPORATION

Date: December 2, 2024

/s/ Thomas F. Cowhey

Thomas F. Cowhey

Executive Vice President and Chief Financial Officer

0001193125-24-268490.txt : 20241202 0001193125-24-268490.hdr.sgml : 20241202 20241202095053 ACCESSION NUMBER: 0001193125-24-268490 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20241202 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241202 DATE AS OF CHANGE: 20241202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 241517625 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d803850d8k.htm 8-K 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 2, 2024

LOGO

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	001-01011	05-0494040
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)


One CVS Drive, Woonsocket, Rhode Island		02895
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	CVS	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 8 - Other Events

Item 8.01

Other Events.

On December 2, 2024, CVS Health Corporation, a Delaware corporation, issued a press release announcing the commencement of cash tender offers for (1) any and all of its 4.100% Senior Notes due 2025 (the “Any and All Notes”), and (2) the maximum principal amount of the following series of notes for which the aggregate purchase price, not including accrued interest, payable in respect of such notes, does not exceed $2,000,000,000 less the aggregate purchase price, not including accrued interest, paid or payable in respect of the Any and All Notes validly tendered and accepted for purchase: its 2.700% Senior Notes due 2040, the 3.875% Senior Notes due 2047 issued by its wholly-owned subsidiary Aetna Inc. (“Aetna”), its 4.250% Senior Notes due 2050, the 4.125% Senior Notes due 2042 issued by Aetna, its 4.125% Senior Notes due 2040, its 2.125% Senior Notes due 2031, its 1.875% Senior Notes due 2031, its 5.050% Senior Notes due 2048, the 4.500% Senior Notes due 2042 issued by Aetna and its 1.750% Senior Notes due 2030.

A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated by reference herein.

Section 9 - Financial Statements and Exhibits

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

The exhibit to this Current Report on Form 8-K is as follows:

INDEX TO EXHIBITS


99.1		Press Release of CVS Health Corporation dated December 2, 2024

104		Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d803850dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO


Investor	Larry McGrath	Media	Ethan Slavin

Contact:	Executive Vice President	Contact:	860-273-6095
	Chief Strategy Officer &		Ethan.Slavin@CVSHealth.com
	Chief Strategic Advisor to the CEO
	investorinfo@cvshealth.com

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Cash Tender Offers

for Certain of its and Aetna’s Outstanding Notes

WOONSOCKET, RI, December 2, 2024 – CVS Health Corporation (“CVS Health” or the “Company,” NYSE: CVS) announced today that it has commenced cash tender offers (the “Tender Offers,” and each a “Tender Offer”) for (1) any and all of its 4.100% Senior Notes due 2025 (the “Any and All Notes”) and (2) the maximum principal amount of the following series of Maximum Tender Offer Notes (as defined below) for which the aggregate purchase price, not including Accrued Interest (as defined in the Offer to Purchase), payable in respect of such Maximum Tender Offer Notes, does not exceed $2,000,000,000 less the aggregate purchase price, not including Accrued Interest, paid or payable in respect of the Any and All Notes validly tendered and accepted for purchase (such maximum purchase price, the “Maximum Tender Offer Amount”): its 2.700% Senior Notes due 2040, the 3.875% Senior Notes due 2047 issued by its wholly owned subsidiary Aetna Inc. (“Aetna”), its 4.250% Senior Notes due 2050, the 4.125% Senior Notes due 2042 issued by Aetna, its 4.125% Senior Notes due 2040, its 2.125% Senior Notes due 2031, its 1.875% Senior Notes due 2031, its 5.050% Senior Notes due 2048, the 4.500% Senior Notes due 2042 issued by Aetna and its 1.750% Senior Notes due 2030 (together, the “Maximum Tender Offer Notes”). The Any and All Notes and the Maximum Tender Offer Notes are referred to collectively as the “Notes.” The tender offer for the Any and All Notes is referred to herein as the “Any and All Tender Offer” and the tender offer for the Maximum Tender Offer Notes is referred to as the “Maximum Tender Offer.”

Certain information regarding the Tender Offers is summarized in the tables below:

The Tender Offers:

Any and All of the Outstanding Notes Listed Below:

Title of
Notes

CUSIP
Number

Original
Issuer

Principal Amount
Outstanding

Maturity
Date

UST Reference Security

Bloomberg Reference
Page

Fixed Spread (bps)

4.100% Senior Notes due 2025

126650CW8

CVS Health
Corporation

950,087,000

3/25/2025

3.875% due 3/31/2025

FIT3

+25 bps

Up to the Maximum Tender Offer Amount, such that the Maximum Aggregate Purchase Price across both Tenders does not exceed $2,000,000,000:

Title of Notes

CUSIP
Number

Original
Issuer

Principal
Amount
Outstanding

Maturity
Date

Acceptance
Priority
Level⁽¹⁾

UST Reference
Security

Bloomberg
Reference
Page

Fixed
Spread
(bps)

Early
Tender
Payment⁽²⁾

2.700% Senior Notes due 2040

126650DP2

CVS Health
Corporation

1,250,000,000

8/21/2040

4.625% due
11/15/2044

FIT1

+110 bps

$30

3.875% Senior Notes due 2047

00817YAZ1

Aetna Inc.

1,000,000,000

8/15/2047

4.625% due
11/15/2044

FIT1

+121 bps

$30

4.250% Senior Notes due 2050

126650DL1

CVS Health
Corporation

750,000,000

4/1/2050

4.250% due
8/15/2054

FIT1

+136 bps

$30

4.125% Senior Notes due 2042

00817YAM0

Aetna Inc.

500,000,000

11/15/2042

4.625% due
11/15/2044

FIT1

+122 bps

$30

4.125% Senior Notes due 2040

126650DK3

CVS Health
Corporation

1,000,000,000

4/1/2040

4.625% due
11/15/2044

FIT1

+119 bps

$30

2.125% Senior Notes due 2031

126650DR8

CVS Health
Corporation

1,000,000,000

9/15/2031

4.250% due
11/15/2034

FIT1

+92 bps

$30

1.875% Senior Notes due 2031

126650DQ0

CVS Health
Corporation

1,250,000,000

2/28/2031

4.250% due
11/15/2034

FIT1

+87 bps

$30

5.050% Senior Notes due 2048

126650CZ1

CVS Health
Corporation

8,000,000,000

3/25/2048

4.250% due
8/15/2054

FIT1

+156 bps

$30

4.500% Senior Notes due 2042

00817YAJ7

Aetna Inc.

500,000,000

5/15/2042

4.625% due
11/15/2044

FIT1

+130 bps

$30

1.750% Senior Notes due 2030

126650DN7

CVS Health
Corporation

1,250,000,000

8/21/2030

4.125% due
11/30/2029

FIT1

+106 bps

$30

(1)

Subject to the Maximum Tender Offer Amount and proration, the principal amount of each series of Maximum Tender Offer Notes that is purchased in the Maximum Tender Offer will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column.

(2)	Per $1,000 principal amount of Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date (as defined below) and accepted for purchase.

The Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated December 2, 2024 (as it may be amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a more detailed description of the Tender Offers. Copies of the Offer to Purchase and the form of notice of guaranteed delivery with respect to the Any and All Notes (“Notice of Guaranteed Delivery”) are available at www.dfking.com/cvs. The Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Notes. The purpose of the Tender Offers is to retire a portion of CVS Health’s outstanding indebtedness. CVS Health expects to consummate the Tender Offers with the net proceeds received by it from the issuance of subordinated debt securities (the “New Notes”) subsequent to the date hereof.

Any and All Notes that are tendered and not validly withdrawn, or in respect of which a properly completed and duly executed Notice of Guaranteed Delivery is delivered pursuant to the guaranteed delivery procedures described in the Offer to Purchase (the “Guaranteed Delivery Procedures”), at or prior to 5:00 p.m., New York City time, on December 6, 2024 (such date and time, as it may be extended, the “Any and All Expiration Date”) (unless earlier terminated by CVS Health as described in the Offer to Purchase), that are accepted for purchase will receive the applicable Total Consideration (as defined below).

Maximum Tender Offer Notes that are tendered and not validly withdrawn at or prior to 5:00 p.m., New York City time, on December 13, 2024 (such date and time, as it may be extended, the “Early Tender Date”) and that are accepted for purchase will receive the applicable Total Consideration which includes the Early Tender Payment (as defined in the Offer to Purchase). Maximum Tender Offer Notes that are tendered after the Early Tender Date but at or prior to 5:00 p.m., New York City time, on December 31, 2024 (such date and time, as it may be extended, the “Maximum Tender Offer Expiration Date”) (unless earlier terminated by CVS Health as described in the Offer to Purchase) and that are not validly withdrawn and that are accepted for purchase will receive only the applicable Tender Offer Consideration (as defined in the Offer to Purchase), which is the applicable Total Consideration minus the Early Tender Payment.

The total consideration (the “Total Consideration”) payable by CVS Health for the Notes will be a price per $1,000 principal amount calculated as described in the Offer to Purchase in a manner intended to result in a yield to maturity or first par call date, as the case may be, equal to the sum of:

•

the yield to maturity of the applicable U.S. Treasury reference security specified in the tables above as determined at 11:00 a.m., New York City time, on December 6, 2024 in the case of the Any and All Notes or at 10:00 a.m., New York City time, on December 16, 2024 in the case of the Maximum Tender Offer Notes; and

•

the fixed spread shown in the tables above.

The settlement date for the Any and All Notes validly tendered at or prior to the Any and All Expiration Date, or validly tendered pursuant to the Guaranteed Delivery Procedures, and accepted for purchase is expected to be December 11, 2024, the third business day following the Any and All Expiration Date.

At the Company’s election, the settlement date for the Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date and accepted for purchase, may be as early as December 18, 2024, the third business day after the Early Tender Date (the “Early Settlement Date”). Following the Maximum Tender Offer Expiration Date, the Company may accept for payment: (i) Maximum Tender Offer Notes validly tendered and accepted pursuant to the Maximum Tender Offer if it does not elect to have an Early Settlement Date or (ii) if the Company does elect to have an Early Settlement Date and if the aggregate purchase price, not including Accrued Interest, for the Maximum Tender Offer Notes purchased on such Early Settlement Date is less than the Maximum Tender Offer Amount, Maximum Tender Offer Notes validly tendered after the Early Tender Date and prior to the Maximum Tender Offer Expiration Date in an aggregate principal amount for which the aggregate purchase price, not including Accrued Interest, together with the aggregate purchase price, not including Accrued Interest, paid in respect of previously purchased Maximum Tender Offer Notes, does not exceed the Maximum Tender Offer Amount.

Holders who tender their Any and All Notes prior to 5:00 p.m., New York City time, on December 6, 2024 (such date and time, as it may be extended, the “Any and All Withdrawal Deadline”) may withdraw such tendered Any and All Notes at any time at or prior to the Any and All Withdrawal Deadline. Following the Any and All Withdrawal Deadline, Holders who have tendered their Any and All Notes may not withdraw such Any and All Notes unless required to extend withdrawal rights under applicable law. Holders who tender their Maximum Tender Offer Notes prior to 5:00 p.m., New York City time, on December 13, 2024 (such date and time, as it may be extended, the “Maximum Tender Offer Withdrawal Deadline”) may withdraw such tendered Maximum Tender Offer Notes at any time at or prior to the Maximum Tender Offer Withdrawal Deadline. Following the Maximum Tender Offer Withdrawal Deadline, Holders who have tendered their Maximum Tender Offer Notes (whether before, on or after the Maximum Tender Offer Withdrawal Deadline) may not withdraw such Maximum Tender Offer Notes unless CVS Health is required to extend withdrawal rights under applicable law.

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to amend, extend or terminate the Tender Offers with respect to any or all series of Notes if the conditions to the applicable Tender Offers are not satisfied. The Tender Offers are not conditioned on any minimum principal amount of Notes being tendered but the Tender Offers are subject to certain general conditions as described in the Offer to Purchase, including CVS Health having issued New Notes in an amount sufficient to fund the purchase of all of the Any and All Notes validly tendered in the Any and All Tender Offer and all of the Maximum Tender Offer Notes validly tendered in the Maximum Tender Offer, subject to the Maximum Tender Offer Amount, to pay all Accrued Interest on the Notes purchased and to pay all fees and expenses of the Tender Offers, on terms and conditions reasonably satisfactory to CVS Health. If CVS Health does not receive net proceeds from the issuance of New Notes in an amount sufficient to fund the Tender Offers, CVS Health has the right not to consummate any of the Tender Offers or to fund them with cash.

CVS Health has retained Barclays Capital Inc. and Mizuho Securities USA LLC to act as Dealer Managers for the Tender Offers. D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offers. The Offer to Purchase and, in connection with the Any and All Notes, the Notice of Guaranteed Delivery may be accessed at the following link: http://www.dfking.com/cvs. Requests for assistance relating to the procedures for

tendering Notes may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (800) 487-4870 (for all others toll-free). Requests for assistance relating to the terms and conditions of the Tender Offers may be directed to Barclays Capital Inc. at (800) 438-3242 (toll-free) or (212) 528-7581 (collect) or Mizuho Securities USA LLC at (866) 271-7403 (toll-free) or (212) 205-7741. Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, any securities, including the Notes or any New Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Board of Directors of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offers. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offers, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is a leading health solutions company building a world of health around every consumer it serves and connecting care so that it works for people wherever they are. As of September 30, 2024, the Company had more than 9,000 retail locations, more than 900 walk-in medical clinics, more than 225 primary care medical clinics, a leading pharmacy benefits manager with approximately 90 million plan members and expanding specialty pharmacy solutions, and a dedicated senior pharmacy care business serving more than 800,000 patients per year. The Company also serves an estimated more than 36 million people through traditional, voluntary and consumer-directed health insurance products and related services, including expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company is creating new sources of value through its integrated model allowing it to expand into personalized, technology driven care delivery and health services, increasing access to quality care, delivering better health outcomes and lowering overall health care costs.

Forward-Looking Statements

This press release contains forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.

EX-101.SCH 3 cvs-20241202.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cvs-20241202_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 cvs-20241202_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g803850g1130075131000.jpg GRAPHIC begin 644 g803850g1130075131000.jpg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end GRAPHIC 7 g803850g1130080611633.jpg GRAPHIC begin 644 g803850g1130080611633.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Dec. 02, 2024
Cover [Abstract]
Entity Registrant Name	CVS HEALTH Corp
Amendment Flag	false
Entity Central Index Key	0000064803
Document Type	8-K
Document Period End Date	Dec. 02, 2024
Entity Incorporation State Country Code	DE
Entity File Number	001-01011
Entity Tax Identification Number	05-0494040
Entity Address, Address Line One	One CVS Drive
Entity Address, City or Town	Woonsocket
Entity Address, State or Province	RI
Entity Address, Postal Zip Code	02895
City Area Code	(401)
Local Phone Number	765-1500
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	CVS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports cvs-20241202.xsd cvs-20241202_lab.xml cvs-20241202_pre.xml d803850d8k.htm g803850g1130080611633.jpg http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d803850d8k.htm": { "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20241202", "dts": { "schema": { "local": [ "cvs-20241202.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "cvs-20241202_lab.xml" ] }, "presentationLink": { "local": [ "cvs-20241202_pre.xml" ] }, "inline": { "local": [ "d803850d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-12-02_to_2024-12-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d803850d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-12-02_to_2024-12-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d803850d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.cvshealth.com//20241202/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001193125-24-268490-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-268490-xbrl.zip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

&O*&9A0R(>!$9OVYQ^0">D!E/^>* M83YJ60%W7,>9C!? T^DTIX;'#I8O\M@C#T!9@&*"FU&_F_?/[4-4=L3+/B'$(L.LS18'6 = M6"S[\DOGTQ+< M+>@+6L+D?-M2UZB(K=::6(; 5_F@,01-%Q04\0R*.J,6_/&Y;[-Z.?M;+1]\ M/*N-F4\)=L^R?T_XTVVFX3H^<_QL#T0S0\S@VVW&9S,_KX;+0Z]\," AI-9W MK7F]9O$G(OVYS6XS%I>>3>1])PA5?+KZ"40'$Y^]V8.1;\^!]L.GSNM&JI M?/8$(G:5J0^H+=FNF3<2IP'S"VJW'(O-?F/S)'42 ,\DCX;_KHIEK9#$+[_& M2<$&3("191*^H\VI2F4;8*Y3FC0U$QK1VXSD8\]>/!L)7"08MVQDTG(S:46M M5)C"15G=/4<^7.S* M5WZ4Y$\%5I=C6DKF+6'M2-NC'%J\57;N&# 6>"* JR MC7:GT?IME3_KG1'KC>-[P$#76GP%DR/\>^JS^A*WJ.>R;8FKE0(;M2RF7S,B79M;Y ?%'BU3_]L/^I5V4\M[:1,5=D]DO'BBV+!%&(0D M%T &P)JLY/]A5;V\^#Z@8V[/JST^9I(\L"GIN&/JW*BV:8!WW[6MFPWL^?VA MU6O>DV[OKM?LIJ.CO1(ZW6;C]TZKUVIVR=W#/6E^:7R\>_BU21KMSY];W6ZK M_7 0CL8Q2KI<3&0C-O&K\DHR]:'=^4QJTJ/.P@R-N,^R\,1D MX"FG@GJ9>FK\<.^:$PP?8C'6"\*'Z^M,$,NM.N=:'O&JOPO/"83G*,H.YJC3 M?.B13O.QW>E]>^/S.!%R C$T\5W292:*']$+I-TA>NG?2=48B F/0)>P)( M(E0SLRZJZ1E&9"$>51C5#**K9YN*(!U%<^%7+1A@#-U'%IW/ 2/FQ$U)&;!G M)AOW(>XT+@D.DK0K[P9E#X-R"%W2E"PINQO(=E;CXR&1PKS-#"$G*)>TH:X7 M-*VL7>GZ5:&0^Y<'N2JU01X^M7]M9U8#:#VG:Y5K X+HD-Q:SM!UZ,L=R($. MT2VC> S=6O6V!"LR63[+!CEH=5?E8"75;W? [M[U5."G7"4YR,1IQUC>>7-& MP92A 4"+(1;H$RJ)])B)69U%N$.X+PD8/S @8MTTOZODT57RK.;3OLV(R6P; M@SLL(6>TC/KN4VGD'15+42SJD4Y M*R FU&]K58\+Q9^P9A%O>&+"YR:U0ZH&*UT'"GL;^_6.4$Q QX>IY4,41=3J MT2'+]@6C7[%FS"U6I4\N2,&SR)-9G9'$!(:L2$Q5R0I96P#P'2+SN#%9U\\M M@7M@7%J.Z0KPX^=&O7[UC[<7\CX.OA)R/GB1"F@]P=N,VB#V.3ER5)9PX*9GM5T3==3B?>& M:;B=1#TZ:X7%/U/1Y&!ZZ4"O4E8K5HI:4=LF;2=0\_*K:/FY4EWB"N+Z(XA[ M_P79A;2X2H!J?9''O(/'5?WB+0O(><,=C[F4$?*H-"20@K>-=ZO3)X!?ZY?]7+U_2CN*GB^6WZZRJ M'V 3C4R][3""R<2]X$\))WR9GM"OH-. CVW11KOF5^2_% M1)G MGB$<(.KO>>3!2_E8J;>&4& 1%K2IH[U5@*8H\K9HPL$L/_)O1=%@DM: ME<#Y&N5*Z7_3[X;$PD37$R!VW*,V83-F3GQ0*G@,MI_)M^VU@,<$F;R7:WI> M+?(H!85E >1O/Y0-_?I& AELYHU<,&"."@LN,;JQ)^C="&04%,051";=<*#5 MN@.X V7["JA7U/2+Y*&"%Z<)GUS@WB,N[>"P]SI3O[XJ9?62EA[T'E!G/@IO M/X#1A7@U*!8)98/A*PVT"K@Z($%U'#0 C3JQJ8RJSE7RD+][+QN=8&MH%VN BP?1A^M%W9Z3/;'>*?,-&Y.YN75 ;?T'UJE(?A10^Q%7+V,M9-!_5K0OY=+S6R,IG^ZV>A) MTJS6GX+[P"_,VR9.F.W(@R.PONO:?0J\\D&RXI:MC/2N7!>+-TG#ML/#JG7$ M^$Q664L.MGIK!W<@L@UH \2($X=XL:W*S@3$I6B40E'U5W<(<6/P7+\FC0\= M8A2T' !>!%J^5PKY+K^[Y;<+IM@$:CO#SV#(P)K9IQ/>ROQ..9=&XZF#8^"H27'(Z+J: \Z M8M$>#%X0C>ZK%17M>]**G2(*%,R:,1)&HK_+!^RA25;6..]?'%>7@C'?M>DU MM*DEY82)5]$I_5VG]M*I LL6S\WCZE0XYMXZ=>P,+18_!JD0$Y!,>#KWY'8GR^[&#X]9%]RA>I"QQ@W+L?39)7Q7YHYQU[N%-L> 8 MHSDBIDVE7"CF2:BNS.Q\#V+F\>*?8%HH]A*?>E("QT'T$ M._ . 7V ITMSO.H4WMRVY8Z4.7 P<]WH*[5Z>:&Z@O<7P8D#A;J^:WZ])!X5 MY(G:$T9^U'*:3CR\0C;:>%3HFVRHI-$DU)= 50X@2$&=\GSCBXT$( J27G)O M-1'+HLHD]ELK15 L$/)_N.)K("*+R&PCC5XKQFHY%H:=C/3GQ%05<1CQ*Z@Y M4X=PULK07!*(&R%TQ4F'9"CJ*!@![-@8C[K]JGHU@DZGR]Y*6[*W$](+Q'JP15!QIW6C MU//$OLL(9)K9D&6 3#NNRCDFDBDHH%>XNX.O&N!JXR:X9HOT47/9. M+*B>D@'I^URFW>.R['=\*S?88 RW&<_.-LJBSL8)6<1'L="FSX#;$-K84SJ7 MF>#RPEEMM(B"(/=S1?6'BOH7W>8H>+-X?F?:C IT?2.529WMV,<][GWKL]>[ M:J%2^J7\EDF6M)6;:>)-++E^\>-X-;I?VIW[9B?;:'_Z=/?8;5:C#V^Y1J?K M&XMT1'T$Y4A6G)+D;OELC =.-/VF#$%H\@A/?+!O54;;EI,$JXP+28X\IPYU M=0QGTG9(=!LO$+'P2MZE.GKX4;VO1[VR)#R8?$DHB2X&$#/^G&/A%*@.QAU/ M7 EP+13<"74-S M(YP#NXSIC(\GX]@I,3I&OY4\DR#!#S)UHLQ14R.Z0>:HSEL,A^!BT?V":P.O M!12 (4UVJ5QL[!24:8J)"B8QU90^)E5SI=807L(#CP6AG)S P&JB2V*Y,!T. M U$X@[X_&I=@]Z,?DM07];G*?9 W,U.W&993@ACO4%3![<"R-Z.L2I3KI,=\ MD5OV/.0U"@IRU329A_$'$C'"HJJX;.2N4[A(ZDD:(@7"P MZ0C8-\^Z4XS?Y:0/YHE3,2=WS'0G$NY"N33*&W&O!1B#A)LI&!NQ#!74T1CIO;0+D-ZI4$4] !"3Z57!%'* M:2F8%\L1YJ4TKB0P5QP.)KY.&182HRTW(H.KTH=:N#NP.=[B;-&J<<*)_[I%+) 6$"W59'GB)[%RQR\9X>U94[6Y=2/GW(48&0 MX\,B[E;'K<SRUPV66]4MK;3$?8 MAVS9IJ-'B:=Z*GL.[ =8$U5(:4R$P' G?%D#Y-+//GB)ADJ&08BL;EF$L<>K MEXYR,KCU<-_\0GIMTOSRL?5+J]=-MRS*CI]R3_(XIF>/3V0#"! M$@GVW'BU^VQ[;5H)J=*K.G&[ M:U?'^YZOW>:";]Q] 0@_M*IH 3^[PD7882SWV;* MY:;:N36!=-:D$ZQW*S\?W'O!:?H0%<-JH<$-7J/29R-J#S!KP(%4?!("8.XP M<:"/&@YX,W(%+,Q*1"K_"_YTW8.NG=PKH2_FWC7>4#=3P@?5M!H_'!?LFT0C$;GQK7'5S0'9P0>IIQU;?,QU@7N9);P2?)?F0@RAZ.F+S5S[;]'W;DI/8 MIR1'WKGQ[;C17+P3X ]N,H)IJ'K%N2J!-4:<#6*UU;9Z;8#8E*FLIQBU?/"_ M%JC_T*#^7U!+ P04 " !:3H)9P A(-I8: OL@ $0 &0X,#,X-3!D M97@Y.3$N:'1M[3W[4]M(TK^[RO_#%/LH4F<;/S 80J@UCR2^A< "V?UROXWE ML3T;6?+J ?']]5]WSXPLR9(Q 0.^>.MR@#V:Z>[I][2F#S[>G)\='GP\;9\< M%@L'-YV;L]/#T_\K[^U5:@=;ZD_X?$L/8 ='%R=?V-&'XXNSBZMW&W]][-R< M;K#KFR]GI^\V;.F(\E#(P3#8_^1Z(VYO'+)B 9X_%DX@O,.#D\Z?9O"=[ 7# M_5:E*9T-QFTY<& "T0\V:)E+,VS$O8%TRH$[WJ^.@[=,_]UU@\ =J8_ZKA.4 M??E?L5^;_MWG(VE/]F_D2/CLD[AC5^Z(PTKML\Z'3^\V/ 1RX_#@Z/#TVU!V M9< 08W:P=71XL'5Y& ,@-GL=9D_!,P/.QN&O3M0T+!$YWS M#^SZZOC=QJ!5;;2:U4&MUJA6=YNU1JU:K5;^'@\0B9MW&V<7'RX4L9X,8(8L MT#XZ.V7'IV=GUY?MX\ZG#^\VJAOT]V7[Y,3\_5?GY.;CNPT Z9<-=G1Q=7)Z M19]K&-0G9>"2L_;E]>F^^67NYJ1W,MHLB[A'48A O#K4OYQ$@#1^@=WBW/4$_UJ6CB][ M8I_?NK+''D;)PQ1$P T;AQWG5OB!Z\7!2H.L>,-PR.PXFNB,>]Z$G5L?/!X, M'SW;N>A)_NA93H,A=]BUS6^E,Z5ODK8Q(L5H]/&T\^'C#6YHQ/:0EVZ0D$U D>/?&30=C:J9;K MNXWR3G6O^0*4?CPAAE+TV74 (B8&$W;1[P.A/?8K'V4_]*#)GT;:*DK:?CO^ M\_JCX'8PK%CN:.5I+2W6[MU*W_58X+)@*, 67KP\Q5>1KE(;'.GTW=^L6W^8 MY))70D]T=\D).LQV0^O;3^B'&M<&'-'W%U>LM)IWYRRJ].ST_;U:>21 MYOB2Y.(M 1B08::$F!V[WM@%49"NP]J.XX:.!4\?Y?28#GW&GQ]HB=$CL1EAAUA:=8L5YB]6I]FP&0S>I;ED/Q M3<1A]^WT6_R[]9:A.@)=I+]U1V/N3$KZNT]?P.7&"=\ *=2&]4!Y]?@$GN$! MT(@-N5\L@."-!'UIX6X&:C==M9N;T^D3VVP602(+;@T9SQBEQKQAN#F;M3<* M88"0GN*V;79JNX(1!+L6CH21:FMZH4#"-.,0M/6C;7B41ID%\,/-NEX QX_X M-SD*1VP,6L:28VXS/@(*!+@B?%\L]%W;=N^0$WSA25@/OCC7#\51T-!L&PL+$+%#V'Y?+!+K.<" M\ B!^&8)T2L6?JZ7('XT_]A!Y] 6OG^PU3E\%!H(()@7($DVH#CWS.ZQ6PCX M>_9$LQQ,1WQA66(@X@]1@@-+69$Y\H%G*P4_CG3=JHJ1&U7/S-B&:E MF@/Z=LN WLRC\@SHM/MJX=V<:1M54 ?N0,#47OZN%PLQ&="TKK";3!;$OW"> M.;+//0&L#'][I#^9!7L-; UA#FPY2.\4#!I?T9H1UXOK4N+G;#F0?F(!0$Z M^"2FCC\TJV(-&L5"YHISD$LMG5@SZSHK;].1&T]AR=!*]D3*"J)D\4C\( M8\(<%0N B!^.8%E8(-*D :HB7VGL_7DPMYX"9G!#;M* [=_G8^SDK!R(;P'X M[A@^[V__\G!(:%GX7^K+\R5X>@KS?EQ%QMS(";@/CIXN_KMH)Y<620LM)?VSSR3ZIRK(E;#L%U#T(*+4G W#YW/[!T=4A MZ1.C-1X3D!OD8]G1E+P:8MR/IXIF/U]W+@G$$.,O!>-]\+TJ#"X\"7O,;42B M@][3*B)Q:6(RM:;RS1&CF%5:0;3.>1!Z,I@@)B<003T?"H\"^_/UC5KA"MU MS .H/Z^%I=!9"(UGI/.1[;HHOH,4V$CW2U#"*\@Z[^4WT=-D'X,)T;]O=L?^ MFP>@DSX[C,[G?X*06O3[&\^0'7ZHB=(?X9$_T4>,DJYOV7SX(/]W7D+I>\V2 MLL$+L%/VP%3)0:V^L].L'O_5^JXEG@9F$)@'PWW\Y[5Z6J4A<8Y8GO)!:S\Y M6C\_&)N]9K54;>UB*NP%]^&A4#>VZLTMQ_*I70./X_-N6]F,DTYL265D*?3E?C0 M=I15-QE]=HF)ZV*!6Y[K^Q"H!>88S4_G[%DR98\9&9V>61=\;=3VUEF95]?"S=6;G13,[;3I(YR8U MXD$HK)$X$[?"/KC^G.$[@#/_EMT*+Y 6M\OD=>U38+]9>W.P!8\,%-6*]6;40RZ0NF4UE8=$U'; MRX5YL5Q9;7E3;U=VZLU?U-,@OL@TM=I6#=.$V]N/,X79"[[OW"P1G7_5:E66 MRG\][0H_-ZI+B_Q>N\Z?5]CX.G1^M=JJ[7YI_Z>V0IIF6NOY$D!_CT:/9157 MB,XMK=9V7X%&KZ\U^L(:O5Y[?HW^X_KU\ZK*7X>.UW[]V4OJ^._TZ]G_A$N_ MNY(._?86^O/-U^#/-Y:I_5%\$]I?V[WF2BK_QL[:G5]BL5/NZT&O0]5K=_Y\ ME?3,JKGSS95TYB.7=KG9O065[MJ;7]R;KZ^]^5>AXE^7-__[2Y;:_=#>_*JF M8[E) MO\54S,ZSIF^,NF^LHKK?6WO[SZC_YUV\\JKT_Q\OJ7I^ M5=NO]&%M\P4.:W]<;W_>%8FO0__KX]M_+[?B;GU\NWH*OOF*3F_WUMG[A35\ M8UU=O\3L3?[MM:]#G^OLS:>7U.<_M#^_JMD;_3)5XS4(WK'?DKV^'>/LW0/,&!O60JHZ[#[-][B?__U M1W3+]-C32EG=SY[5@('Z1>2U74A'1- @)+=R0P&R](8)OPL!.. % +X(^^ MI+?7WS#L;2#[TH $0%JN'8Z<"HNL/$F"D8-BY@7:.VLYR)"#^BN4@TM@L)_I MW#V3J>?,E(L9/0V/D<=TV3<,Y=TY_R _ M=^:J>VJ4T!5XI_R(]P0+QZZ^A1^$475:\).ZQ'*=GD1=X8,Z"! A$$_I% N9 M75!8CR/:IGT.,YUSD$XR@#4G*/M\A#!1*Q(_!"D7>&$$4LMS1RP )&AQ^!GO M'S&S5M2A0W5X >A\#1YG(]_#4+N<0"?UK'EK? F2H>9UBJ:D+,M)3:CCA1ZJ@_3 MJ4[T5%'W',"'WP(Z2A\&[.[NKM+K?X6=Q*Y<6]:MK]IGS&ZW.Q8.]8V A3TQ MP"8"R.!#UZ:K[$"#]N2M[(7P_:04]0CZ2%]/6U=@#Z)I3XWXQJB149\?34/5 M9X- @$8N[[()#T:#H#-$X%$#!F$"V:;DHV4L#F4&VN)@/%?%YC&$3[NW[0E MD_B&5/=5%Q"'^DT$(F/AR,XXP-9@$?$>/VRT80G 4'>-(8Y4K(Z-4,@ 44L? MO!Y%.L3K" 8P']UJ@SP4ZX6$DICH@81M9\0_(7"[X0J4%VHFXO8K2V_8,5W:,OH925,"SR:9A.T;UT7V3M,^D16AT0AV*;T3] M7ERHXEMU^FTL=8\QM#J&F39#!_M"@:OFV1+1)7^*>!*8-R81? Z% /-I ZN( M&[+[.Y'KI@4D[:'=N &8VF.7_ G3$&W&."Z?Q>>8>(.=:< S978VP^N/W?Q: MXU&[/^-IQ)NH??\N%0M9VZ2$6/4-$_ZLIZ,O=%JL"UIEGI.5H6WZ@?"RG2O6 M#8/';@,VP<)M $?MN_8A$Y=EBN.4D,FMSF'2>[FA6$BP@^N@BYN2W#AN^0(\ MI^^=9B!_$9T ) GS>4SK![P[>+QH.W86UQ"M5"3V;.TMZP;RXOI"Y^\,5 )B M%RO)@;'6EK/<9$3/]#-,RIGIK*9TC\D[\&*!&A*R\9Q8T>*V%=HDNPM)*Z4P M@ B.(]!%4HI$^;5^: ?JZXD4-GTXTG=5HFKK2\\']Y-[N*9-"JID.KQ9.+/2 M3B4&;B/ I_TA\&K!CU+=TM8YBUC.HOE+5H)7?]F8F]! 9MK+>JR6>BQC@?G9 MC\2W#TZ%+'K:AGR1P6+]M%;^7+F&L PHZ8?@17OFZDL3PDS22;.H0Q_ONF!" ML!MM+'<'QJ=60ZO,%['*S#C%>F;B\-S6HR >.'UU\>EK<^;/]TM4:\9U1G M M7?.EJX\7LH)XX&VLS!^Z=TZ6A"R26W[RL ?MIR^"0*72E)^;W\MTD63GG "4 M$@$SN!CA[[$ M7!##WMG3SM'WH%*9,:%/GW11?29TXV^3RA*42C,G,'E;]]0)ZQF:@S.DB5Z* MDK,JA*&VN2FRM^XA^[QH+N;)J2^OISC'PJ@*>Y_8NT4BL%*"9S$?NFQ!B&VS@$/.5I/AV5BCUNW*0V$LI_ MB.9:\6+BO4?@"_#<][8-=H. Z&R"090J+(4Z=K,\B.'G M<)LZY8R)0O:FIQB)_'0G3KAT8/ T#>6!876#[-AIY^.ZNB?SLF"B;J4;^D"5 M:)^*A0T"O7]CZKG+%D2GL6"_>,+[$XF4FS1+#E41O1 M049)HC0[3J?#/ AY6-+6*A6=. MV6;"]'U<,:_/_5SVR!'Q^QDE>\GO8I@YP&_>#9724RDMV@.,\2(]OB@4;V:8 ML%@@$LY97+-C+#\D'\66K\X[*XV=9R,/XLZ!L$]KA!2=M?,1*QO0 MJBLGY>Q'^6T?#+&/>8>\@VP<%,V+!LUU"!( FW8]J^1# :4J'B).Q9.%621Q MB1C-+.$%'&@[$([P5&+28+103K 4,]JQS029H>-K;"+48]$)L7$]%.!^V.]+ M2^ISXGZHJP^F67W #(F?FSJ9<98TE/&1"2$A/WH*X4S!FJX0FPV!ZCA8#J3"A_9 Z/ @8\F;O)HB MU!&X6XY*!D310-)QTRZZ/LN84T-A(GB(5WU?I014T9(Q]6 \O^ZS81",][>V MLBJ(KK ZQ5>%5("Q+WU5=>D)&_!$'>KJDM&H^ )'KNJI76-]:O<803:5%,@8 MT^ BWO!J3+9NWN%1DCE%$Z8&'%I(]<"+_XV94W*-\+7XR&8?;99K]7?L(/W M%Y]N(O2',A!E?\PML>^X=QX?;QS6=_;*S2;>08TC#]DF\FF7.U^5SN]Z[E>0 M3?0A[,D;2K^TJM4%YMUN[9;A7W)>LIR(!7H[MEWN>P)+(1:5IDQ3E*FU,^B; MUII*C0$1XP@5"_-0:K3*C3J^(*A1FN) A%F,X,UZJ[S;;-6B672](,V1K[\) MT)V=179TMU;>W:XV%@!S+KKU:K.\N[M=JYB)CL##0[,+M'/O'$-F;OMD20-4 M_BJV44Q3 N)N-)^#BU?K. O4QQYKV/4%H[ M]5"@NR>CF2L6IO%$B=R4:0UEW'6>GN C'# LIHH:_83&_)Y7AE:8,BL)(@UQZWF@Z-[2QI V#2G[7#^V\B"56:8WA MF3VA?'LBASSK%]#P::TO?&5B[F1I[2?4AHDZ6>4C'+GE3* M6RK-U]%Z0XF_A9@-"".P2F:;%*S2B_89'6,.[JTM.8V3*&:HXFDX0(K"Y/34 MJIS"1I,O<#WB6$,&?TCTURDA^-(3?0]#->5J1R:)*[;$Z6-EQ4J4(^<;H0-) M$"E395PWLR;N9N@-=*H 8J 0O6L+/H;MMU7P(6-DRZV0+RGOW#8Z19TB0DP? M4,ZK?1I8?@ Z"1BPWO"DC[9"$.@($J017AE!#W*X>P#*^:_]Z,+ M]0V5(3;J MO!M*FX9P4 ">32(VU"5]GHN!E" O7$5?>!*$=>&4KM&FG=Q\F,"B5(.K:O=@ M%$SW53D)8^&.4<%@1?BMRHI-D/U3B1-&,S6S7(OX$;HB-@.\7L)MWW,;R &,U1Z)'[UQ9$%1(*S%AO=Y$YH(M MFBA<9\9.Z3T>4I,K9H(:=$@'9 LOJ!IXF7D_8J')55"L#E;\= MT^&G@^D@X >D&.@"3-(+:^BXMCN8 "!@AD U$Z31JP3XG"9=1!MT03 ;1 )/ M 34N@D5X>(: SY?,!#BD*P+,8NM90)V!UM""#U"J,>XM)A)M,XA@L%R(#YY' MR[YWO3OP#,IGKDMF]QK<&CJH]9]#WV:XHN1< Z\6"WT-FJU!\R/0%,-?M;T]U#[NK<1J=O!<>5^ 2O2Z6&VI_N6LI3RO MKG+<'=C2(;?[2=^IPHXFVA([6&*')T.8=LR?TR2NHU=8B+W[(3X,WJ#PR&>@ MM*"GRT6UE"73T>"LZM U='1JFN@0U7_W).8.R;%PD=#HVN+X+9CW'_0X97]2 M02)A':E9" ,=?!!8%_62)_$E,).R=/4>B='8-G7L*I^4BRU>HJ$=J1R L7HP MECH'B8_O*@X__0:.DC,@-3&2/GHZ#-U&4#_)P #AB[^32,M>P;+L/5=^KZ_S M:@H*?8"(\D MMAT'J7TET/^D\XKWR*GWAKJU:OGWDC&T./D?P#T!O6&EYO+90^;ZPTQE\I/_ M1-,! TJWYS-5L7S.P4E-OCI18O\.'9%T-XB>.:X(?8<@'X>>![0H%AX,<:O\ M>Q2;+SL7_<4-27HLQ06B9W+HP/(6!GC(T:"PI!)1)^.MQ)0X@"\1TU[W#D_K M"DYGD"I<[=(1![VCJYPB'&;F@7UTRI8B,KN5XDZK#1]\@K$YS1APCUA=Z1MT M4!VM7O"%/65Y8SJH%&F>V&D=O33"H^@3#\9]]18DQLM37(N%K#,1@D>=0_3" M@$Y2PG%/ESQAF8H_3Z&4HA"'HR[7Y?3X_BUL82S>*B4Q+*64I,G$W$GS&O8J M9JNWYV>KP8A?G'R!#S_>G)\=_C]02P,$% @ 6DZ"64JI+TT1!0 H 4 M !D !G.# S.#4P9S$Q,S P.# V,3$V,S,N:G!G^W_C_P,& 2\W3S<&1D9& MA@0@9/A_F\&9@8.-C9V-E8.=G9V3DX.+1X27AYN;1U)(F%]$5DI>3E9*1D9! M14]=04E'649&PUQ3Q\#0Q,1$7MW2UL+(1L_8Q AD"",G)R7F+B$I)2JFKJ&II:)J9FYA:65LXNKF[N'IU=P2&A8 M>$1D5')*:EIZ1F96<4EI67E%955S2VM;>T=GUZ3)4Z9.FSYCYJQ%BY>OCH\9.GSYZ_>/GJ MXZ?/7[Y^^_[CYR^0OQ@9F!EA *N_!('^8F)A869A!_F+D:D024S%YJ/H1Y#6PSXCS6!-9/H-[ M#.&O6PP\S(S R&,69+!GN/'Q^!'9N--'WB8OL]S6=?) PBG.&5^?VQ]^&;GI M3\BUV3%=7QVB51FC+A1)E#]?5ZN]\^-_AL;)1\3VYVUTV#7%^X#\IROU);]_ MA>M_^'S *.;.NK5K'((DSK]+F%!TQK[C=[C)U+A:N?9+B:]2_S.$/)\3;A2V M/2RS8O[17\<6/Y*V93Y\]EMF:F_LW>-GN'EOO"A@^).M]3KJX[N)HE^G7IFT MVV&1Z^Z(PPSL@3OZ'.46K:LX[']EC^WC$S:^Z6G?P\XP)G3/7:)WB7^YQ.I9 M?(L?V8N_-G=[)JE;$MXZX=#+GDD&;-6_+N^][??=H']SK\4Y0S^S:[_O/95U M/SYK\P]WYVKMM;MZ[[19RBA-*CSX6.+)-9MY!A_-%JZ\$UV?YYZHNO_4Q%VM M?(?7^=G/-3]4)W$E^MBT;]O++J]=.V7=P[E\EYN/OSYK?51;^[7XQZQ[,LG6 MA@(QT4SF5<*O@^[K3-SX^\@$A[7\@ME!)]=55-UV_RC4NF/'ISSEEF-/&R1//GCP,:9V M[]R[[4TFNWV#KCT\LFM)L0Z;T=-D]DGNB;'JW;DFKV6S#_>F+I]QX\Y,.8\$ M>ZVI!U3ZYLQZV7?BYQN?D*R3ZDM_R=36B:?GO0P,9G+?&%- MTK(K?U(7OPP_G6ZSZ:0=LT63V@27Y8LM95DKIVZ=5Y\B[L'8=M]I)+ZQY^*%NX)O+5MNDZUUWE;B4*3CBWR&"WD743O]R7 M,]S;Y^G%.H==R#>)=0N[O&QW=7;'GX7; @2V.2I;LI29SBY]_',K/]_A-;=] M35O*=ATIN\Z5],C#9[=?D=7;YWUSM=5=C6Z]^"<[*];NV4V=KRM[/OYT-UC] M_O;$EY^YHCN/;F_SFUN8693>?"2I,EE 3"[\EOF[7[F2"_@]+]8$+GN]^7QN MUF75(PK&KC9NYEI^S Q5*[^NS;.5_B1Z[,Y=M_UB)MLBGMVX%7-A>L2Y2V<^ M;FJJZ_(MV]^P@#WP^()%75;-P@P] AI+, M%P)_!+HRR+>*!#JP@K :.U #P_^; %!+ 0(4 Q0 ( %I.@EG".-*H/0, M $P+ 0 " 0 !C=G,M,C R-#$R,#(N>'-D4$L! A0# M% @ 6DZ"62'=JL]?!@ OD, !0 ( !:P, &-V&UL4$L! A0#% @ 6DZ"63?ZA;6U! ?2H !0 M ( !_ D &-V&UL4$L! A0#% M @ 6DZ"68R<&5="$ ,&0 X ( !XPX &0X,#,X-3!D M.&LN:'1M4$L! A0#% @ 6DZ"6< (2#:6&@ +[( !$ M ( !41\ &0X,#,X-3!D97@Y.3$N:'1M4$L! A0#% @ 6DZ"64JI+TT1 M!0 H 4 !D ( !%CH & XML 19 d803850d8k_htm.xml IDEA: XBRL DOCUMENT 0000064803 2024-12-02 2024-12-02 CVS HEALTH Corp false 0000064803 8-K 2024-12-02 DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 (401) 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false